QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01071694

Enrollment

Registered

2010-02-19

Start date

2011-01-31

Completion date

2012-12-31

Last updated

2012-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Relapsing-Remitting

Keywords

Multiple Sclerosis,, Relapsing-Remitting,, Interferon beta-1b,, Quality of life

Brief summary

This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.

Interventions

DRUGInterferon beta 1-b (Betaferon/Betaseron, BAY86-5046)

Patients receiving Betaferon according to routine clinical practice

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis according to Poser or McDonald criteria, starting Betaferon treatment, including patients switching from other DMDs * Patients who signed informed consent form

Exclusion criteria

* Age lower than 18

Design outcomes

Primary

Measure	Time frame
Quality of life evaluated by several validated questionnaire	Baseline, 3, 6, 9, 12 months (+/- 1 month)

Secondary

Measure	Time frame
Information about safety of Betaferon in routine clinical use	Baseline, 3, 6, 9, 12 months (+/- 1 month)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026